Long-term use of ticagrelor in patients with prior myocardial infarction.
about
Thrombosis in ST-elevation myocardial infarction: Insights from thrombi retrieved by aspiration thrombectomyState of the art: Oral antiplatelet therapyTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateA Review of the Key Clinical Trials of 2015: Results and ImplicationsPerspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populationsThe risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion.ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathyImplications of the PEGASUS-TIMI 54 trial for US clinical practice.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represDual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist.Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic reviewGrowth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major BleedingA Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Prolonged dual antiplatelet therapy in renal failure: a challenging trade-offCauses of late mortality with dual antiplatelet therapy after coronary stents.Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosisInverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.International patterns of dual antiplatelet therapy duration after acute coronary syndromes.Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial.Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.The future of P2Y12 receptor antagonists.Management Strategies for Clopidogrel Hypersensitivity.Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.Oral dual antiplatelet therapy: what have we learnt from recent trials?Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
P2860
Q26746148-71037BB8-CA41-4139-A9A4-1598AA1B68F2Q26746161-3288DCCE-97F9-4398-8ACE-17D71297CF31Q27006031-7B48EC3D-5729-47B4-BF15-D7C12ECD35E2Q28077170-414DDBAC-ABDC-4CAD-B5CF-400BD23C5F16Q28087099-55B20CD8-D0B1-4F1D-9C59-BF8E9FD6D7D0Q28600880-821D1A60-44E8-4344-9F39-72FCDC7FBB93Q30234909-BE64D3CE-2631-4A7F-90DA-6EABE80BD1D6Q30248679-A683A3BB-C920-4640-AE54-743575E49949Q31070055-FBD124C0-3BB7-4E22-9C9F-BFC08FB593F5Q31155795-72DCBB21-0A53-4633-9A6C-D6F065261384Q33589630-60AA3898-EDCD-46B9-B41D-B9BCE767D373Q33642986-39849487-015A-4AA0-B346-E25A3558E25DQ33647497-46CADC36-FF73-4D27-9963-074E330E99C9Q33801831-5175200B-BD01-4463-8AB9-59EACC076351Q33908782-DB4BE801-9FA2-4C99-ACB6-071610654F38Q34046881-F0FFC82D-B46B-4DD5-BBC6-6DA6D2781822Q35972254-6A21BDDE-DB6E-434C-99DA-00EA584290D3Q36114034-BA195228-CBA2-467C-8A82-8E7E73C39A77Q36273176-EE7CA7BC-C36C-48DB-8DBD-F5B276B2D05BQ36347479-00BF8D62-25E5-4F72-877D-175F5D2DA2C8Q36363183-ED8395EF-5E7A-45E0-A606-F06AD36286FBQ36437445-760AC174-099F-4446-80E1-58AC6D973934Q36573521-0075D42D-C0AA-4E7F-8B0D-9738C9E7EE12Q36619562-8E344ACA-1D59-43DD-9270-ED0C7AA8601BQ37198888-59471311-C560-4DFE-AC0A-4B4AF8AE0D3AQ37225795-AD9CBB26-4065-4AD8-8A3A-BE190D9B76F3Q37509443-933EFED7-8E1D-4FD0-B34C-D0344929A8B2Q37617057-6C75445A-6259-464C-84E9-C9530260AE26Q38370738-684A6F4D-18D5-4873-8248-E430E9BBB37DQ38372640-8F3E6127-3111-4B1D-94E9-801AC835A55BQ38377285-ED36C58A-C306-4D7C-BE48-F7771E4E52A6Q38379410-506C9398-18E3-49B7-9C18-01A07411DEC7Q38380436-D39FEE14-96E3-4FA4-BE9D-D3DEF3960AE0Q38388236-028C9C43-D8BD-4560-954A-4062EF509DB1Q38396256-932D2600-52A4-42F8-93F5-5377C246021EQ38515684-09A5A23B-B1A8-4F11-A6D0-82D2D805CB7CQ38521560-A21BD622-1EB0-4494-B8E3-FCFB4B2EF94CQ38540055-BA420081-89F7-497F-9C01-5B0B656BBFBFQ38561878-2C43BFF4-1D7D-4C7D-995D-BE32B0E72E38Q38568711-836D6196-7D08-4B73-A2D4-B888FB9670EE
P2860
Long-term use of ticagrelor in patients with prior myocardial infarction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-term use of ticagrelor in patients with prior myocardial infarction.
@en
type
label
Long-term use of ticagrelor in patients with prior myocardial infarction.
@en
altLabel
Long-term use of ticagrelor in patients with prior myocardial infarction
@en
prefLabel
Long-term use of ticagrelor in patients with prior myocardial infarction.
@en
P2093
P50
P356
P1476
Long-term use of ticagrelor in patients with prior myocardial infarction.
@en
P2093
Andrzej Budaj
Christian Hamm
Deepak L Bhatt
Eva C Jensen
Giulia Magnani
Jindrich Spinar
José Carlos Nicolau
Kyungah Im
M Polly Fish
Marc Cohen
P304
P356
10.1056/NEJMOA1500857
P407
P577
2015-03-14T00:00:00Z